Will Teva Recover From Its Downfall?http://www.fool.com/investing/general/2013/09/26/will-teva-recover-from-its-downfall.aspx Lior Cohen
September 26, 2013
Teva Pharmaceutical Industries (NYSE: TEVA) hasn't done well in the stock market as its recent quarterly earnings reports didn't impress investors. Looking forward, is Teva worth owning? What are the good and the bad of Teva? Let's start with the company's second-quarter earnings report.
In order to get a better understanding of Teva's operations, let's divide the analysis between the generic segment and specialty segment.
Specialty medicines revenues slightly rose
Teva's most important drug is copaxone, an MS treatment. Sales of the drug rose by 9% to reach $1.1 billion during the quarter. This represents nearly 20% of the company's revenues. Moreover, this drug has the highest gross profitability for Teva at nearly 89%. Alas, the main problem the company has been facing is the expiration of copaxone's patent, which is scheduled for May 2014 -- unless the recent U.S. courts ruling will change. This is among the reasons for the lack of growth in the company's stock and valuation.
The situation, however, might not be as dire for Teva as people may think: Teva is developing a copaxone treatment that will change from daily injections to a three-times-a-week oral treatment. Currently, the treatment is in phase 3 trials. Once this drug is approved, it may pull back up the company's stock price and keep Teva's high profit margin from copaxone.
In terms of profit margins, the little rise in net sales didn't change the company's gross profitability for specialty medicines (excluding MS treatment sales). Teva's gross profitability remained higher than other leading pharmaceutical companies' profitability as indicated in the chart below.
Pfizer's (NYSE: PFE) gross profit margin is nearly 83%, which is close to Teva's gross profitability. The profit margin of Merck (NYSE: MRK) is much lower at 75%.
Let's turn to Teva's generic segment.
Generic medicines sales are declining
For 2013, the company projects that its generic sales will reach nearly $10.50 billion. Based on the first half of 2013, the company's annual net sales may reach only $9.4 billion, which is 11% lower than the company's outlook. Therefore, if generic sales don't rise in the coming quarters, the company won't meet its expectations.
Let's turn to see other factors that could impede the company's future progress.
Research & development
Pfizer's R&D as a percentage of revenues reached 12% in the second quarter of 2013; Merck's ratio is the highest of these three companies at 17%. If Teva continues to allocat